DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 21, 2018, reports on a global equity offering by DBV Technologies S.A., a clinical-stage biopharmaceutical company headquartered in Montrouge, France. The filing details the execution of an Underwriting Agreement dated March 20, 2018, for the sale of ordinary shares and American Depositary Shares (ADSs). The offering was priced on March 21, 2018, with a closing date expected on March 23, 2018.
Key Financial Metrics and Offering Details
- Offering Structure: A global offering of 3,527,752 ordinary shares, split into a U.S. public offering (1,392,015 shares as 2,784,030 ADSs) and a concurrent European private placement (2,135,737 shares).
- Offering Price: $21.26 per ADS (U.S.) and €34.71 per ordinary share (Europe), based on an exchange rate of $1.2246 = €1.00.
- Gross Proceeds: Approximately $150.0 million (€122.5 million).
- Net Proceeds: Expected to be $139.2 million (€113.7 million) after deducting underwriting commissions and estimated offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 529,162 additional shares (15% of the offering).
- Use of Proceeds: Funding the development and commercialization of Viaskin Peanut, advancing other product candidates, and working capital.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period. It references the 2017 Reference Document for audited financial statements.
Material Changes and Capitalization
The offering represents a significant capital increase without pre-emptive rights for existing shareholders. Based on the share capital table provided in the press release:
- Pre-Offering Capital: 25,661,438 ordinary shares.
- Post-Offering Capital (excluding option): 29,189,190 ordinary shares.
- Dilution: Existing shareholders not participating in the offering will experience dilution; for example, a 1% holder prior to the offering would hold approximately 0.88% post-offering.
- Major Shareholder Participation: Existing shareholders Baker Bros. Advisors LP (approx. 31.6% of offering), Bpifrance Participations S.A. (approx. 16.6% of offering), and CEO Pierre-Henri Benhamou (approx. 0.8% of offering) agreed to purchase shares in the offering.
Guidance, Risks, and Contingencies
- Lock-Up Agreement: Directors, executive officers, and certain shareholders entered into a 90-day lock-up agreement restricting the sale of securities following the offering.
- Forward-Looking Statements: The filing contains predictions regarding the closing of the offering and the use of proceeds, which are subject to risks including market conditions, clinical trial outcomes, and regulatory approvals.
- Stabilization: Underwriters may engage in over-allotment or stabilization transactions to support the market price, though no assurance is given that such actions will occur.
- Risk Factors: The filing directs investors to the Annual Report on Form 20-F for a detailed discussion of risks, including those related to product development, regulatory approval, and liquidity.
Investor Verification Checklist
- Verify the final closing of the offering and the exercise of the 30-day over-allotment option.
- Review the 2017 Reference Document (filed with the AMF) and the Annual Report on Form 20-F for audited financial statements, as this filing does not contain them.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk, as the use of proceeds is heavily dependent on these development programs.
- Confirm the actual net proceeds received after final deduction of all offering expenses.
- Check for any updates regarding the lock-up expiration and potential selling pressure from major shareholders after the 90-day period.